WP
BMY.RT

Wedgewood Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Wedgewood Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-122,750
Closed -$84K – 40
2020
Q4 		$84K Sell
122,750
-8,807
-7% -$18.8K 0.01% 38
2020
Q3 		$295K Sell
131,557
-3,172
-2% -$9.06K 0.05% 35
2020
Q2 		$481K Sell
134,729
-14,172
-10% -$51.1K 0.08% 30
2020
Q1 		$565K Buy
+148,901
New +$491K 0.11% 30

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Wedgewood Partners's BMY.RT Position: Q1 2021 in Review

Wedgewood Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 122,750 shares — an estimated $84K sold.

Wedgewood Partners first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $565K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Wedgewood Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Wedgewood Partners sold 122,750 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $84K.
  • Wedgewood Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Wedgewood Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $565K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Wedgewood Partners's 13F filing for Q1 2021, filed 17 May 2021.